Subscribe free

Upper Gastrointestinal Tract ·

Survival Advantage with Neoadjuvant Chemotherapy in Esophageal Cancer

Neoadjuvant chemotherapy (NCT) significantly improves long-term survival in patients with esophageal and esophagogastric junction adenocarcinoma compared to chemoradiotherapy (NCRT).

  • Overall survival rates at 1, 3, and 5 years with NCT were 95.4%, 81.5%, and 73.8% versus 87.8%, 64.8%, and 56% for NCRT (p < 0.001).
  • Disease-free survival also favored NCT, with a substantially reduced risk of death (HR 0.49, p < 0.001) and recurrence (HR 0.24, p < 0.001).

Consider the type of neoadjuvant therapy when discussing prognosis with patients.

Journal Article by Risi L, De Martino R (…) Garbarino GM et 6 al. in Ann Surg Oncol

© 2026. The Author(s).

read the whole article in Ann Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Upper Gastrointestinal Tract.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Upper Gastrointestinal Tract

The latest stitches

Ann Surg Oncol20 Oct 2026

Robotic Esophagectomy: More RLN Nodes, More Complications

After neoadjuvant therapy for esophageal cancer, robotic surgery more often included left recurrent laryngeal nerve (RLN) node dissection and retrieved more nodes there—but was associated with more overall complications.

Surg Endosc20 Oct 2026

ICG mapping linked to longer gastric cancer survival

In a meta-analysis of 7,518 patients, ICG-guided lymphadenectomy was associated with better 3- and 5-year survival and greater node yield—but the evidence does not establish causation.

All papers in Upper Gastrointestinal Tract →